Drug Pipelines

Internal Commitments, Out-Licensing Opportunities, and Discovery (NCE) Pipeline

Internal Pipeline
Licensing Opportunities
Discovery (NCE) Pipeline

Internal Pipeline

Formulation Development
Therapy
Indication
IP Filed
Feasibility
Stability
Pre-clinical Studies
Phase 1

BB106
Ketamine

Acute Pain Management

Mental Health Indications

BB206
Flumazenil

Benzodiazepine Addiction

BB605
Naloxone (Continuous Delivery)

Opiod Overdose

Licensing Opportunities

Bexson has validated SeValent™ technology with a broad range of existing molecules across several therapeutic areas. These include, but are not limited to:

Formulation Development
Therapy
IP Filed
Feasibility
Formulation
Stability
Antibiotics/Antifungals

Dalbavancin

Telavancin

Eravacycline

Tigecycline

Lefamulin

Amikacin

Caspofungin

Psychedelics
Tryptamines

DMT / Dimethyltryptamine

5-MeO-DMT

4-AcO-DIPT

Phenylethylamines

Mescaline

2-CB

Empathogens

3-FMA

5-MAPB

3-MMC

5-IAI

Local Anesthetics

Lidocaine

Bupivacaine

Ropivacaine

Opioids Agonists and Antagonists

Morphine

Naloxone

Triptans / Anti-Migraine

Sumatriptan

Eletriptan

Naratriptan

Rizatriptan

Movement Disorders

Amifampridine

Pramipexole

Ropinirole

Levodopa/Carbidopa Prodrugs

NMDA Receptor Antagonists

Dextromethorphan

DCK / Deschloroketamine

D2FK / Deschloro-2-Fluoro-Ketamine

Steroids

To Be Announced

To Be Announced

Discovery (NCE) Pipeline

Bexson's science team is uniquely suited to develop New Chemical Entities targeting the NMDA receptor. We have established a new family of NMDA receptor antagonists with novel receptor binding profiles.

Review the Benefits of Partnership